Predicting bleeding risk in a Chinese immune thrombocytopenia (ITP) population: development and assessment of a new predictive nomogram

Mingjing Wang1,2, Weiyi Liu1, Yonggang Xu1, Hongzhi Wang1, Xiaoqing Guo1, Xiaoqing Ding4, Richeng Quan1, Haiyan Chen4, Shirong Zhu1,3, Teng Fan1,2, Yujin Li1,2, Xuebin Zhang1,2, Yan Sun1,3 & Xiaomei Hu1

The aim of this study was to develop a model that could be used to forecast the bleeding risk of ITP based on proinflammatory and anti-inflammatory factors. One hundred ITP patients were recruited to build a new predictive nomogram, another eighty-eight ITP patients were enrolled as validation cohort, and data were collected from January 2016 to January 2019. Four demographic characteristics and fifteen clinical characteristics were taken into account. Eleven cytokines (IFN-γ, IL-1, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-22, IL-23, TNF-α and TGF-β) were used to study and the levels of them were detected by using a cytometric bead array (CBA) human inflammation kit. The least absolute shrinkage and selection operator regression model was used to optimize feature selection. Multivariate logistic regression analysis was applied to build a new predictive nomogram based on the results of the least absolute shrinkage and selection operator regression model. The application of C-index, ROC curve, calibration plot, and decision curve analyses were used to assess the discrimination, calibration, and clinical practicability of the predictive model. Bootstrapping validation was used for testing and verifying the predictive model. After feature selection, cytokines IL-1, IL-6, IL-8, IL-23 and TGF-β were excluded, cytokines IFN-γ, IL-4, IL-10, IL-17A, IL-22, TGF-β, the count of PLT and the length of time of ITP were used as predictive factors in the predictive nomogram. The model showed good discrimination with a C-index of 0.82 (95% confidence interval 0.73376–0.90624) in training cohort and 0.89 (95% CI 0.868, 0.902) in validation cohort, an AUC of 0.795 in training cohort, 0.94 in validation cohort and good calibration. A high C-index value of 0.66 was reached in the interval validation assessment. Decision curve analysis showed that the bleeding risk nomogram was clinically useful when intervention was decided at the possibility threshold of 16–84%. The bleeding risk model based on IFN-γ, IL-4, IL-10, IL-17A, IL-22, TGF-β, the count of PLT and the length of time of ITP could be conveniently used to predict the bleeding risk of ITP.

Immune thrombocytopenia (ITP) is a hematological disorder characterized by a decrease in platelet numbers with or without potential bleeding at multiple sites. The destruction of the platelets and an increasing risk of

1Xiyuan Hospital, China Academy of Chinese Medical Sciences, No.1 Xiyuan Caochang, Haidian District, Beijing 100091, China. 2Graduate School, China Academy of Chinese Medical Sciences, No. 16 Nanxiao Street, Dongzhimen, Dongcheng District, Beijing 100700, China. 3Graduate School, Beijing University of Chinese Medicine, No. 11 Bei San Huan Dong Lu, Chaoyang District, Beijing 100029, China. 4Dongfang Hospital, Beijing University of Chinese Medicine, No. 6 FangXingYuan 1st Block, Fengtai District, Beijing 100078, China. 5email: huxiaomei_2@163.com
bleeding have a close connection with immune disorder in T cells in ITP patients. However, T helper (Th) cells compose a broad group of immune cells that includes T helper 1 (Th1) cells, T helper 2 (Th2) cells, T helper 17 (Th17) cells, and T regulatory (Treg) cells. Th1/Th2 and Th17/Treg cell imbalances have been confirmed in ITP patients. Additionally, the imbalances between these T cells result in an inflammatory state, which contributes to vascular endothelial injury and platelet destruction in ITP patients. In addition, the differentiation of Th1 cells is induced by the cytokine IFN-γ, the differentiation of Th2 cells is induced by the cytokine IL-4, the differentiation of Th17 cells is induced by the cytokine IL-17, and the differentiation of Treg cells is induced by the cytokine TGF-β. The activities of these T cells are also regulated by the cytokines IL-1, IL-6, IL-8, IL-10, IL-22, IL-23, TNF-α and so on. Therefore, the expression of cytokines might influence the severity of platelet destruction and vascular endothelial injury. In other words, alterations in the above cytokines may increase the risk of bleeding in ITP patients. Moreover, the risk of bleeding is controlled by a complex regulatory network that is built from a wide diversity of interacting molecular components. Nevertheless, there is still little information on the relevance of these cytokines to the risk of bleeding in ITP patients. Hence, it is necessary to determine the relationships between these cytokines and the risk of bleeding by using a model based on multiple cytokines.

In this study, a cytoketric bead array (CBA) human inflammation kit was used to detect the expression of IFN-γ, IL-1, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-22, IL-23, TNF-α and TGF-β. Then, a predictive model was established by combining the expression levels of these cytokines with clinical information from patients. The model was used to determine the relationships between cytokines and bleeding risk. In addition, it is meaningful for clinicians to estimate the bleeding risk of ITP patients.

### Patients and methods

#### Patients

Research approval was obtained from Xi Yuan Hospital, China Academy of Chinese Medical Sciences' Ethics Committee (2015XLA108-2), and all participants provided informed consent in accordance with the relevant regulations and guidelines. Patients in training and validation cohorts were recruited from the Xiyuan Hospital, China Academy of Chinese Medical Sciences and Dongfang Hospital, Beijing University of Chinese Medicine, between January 2016 and January 2019, and they came from all over China. All the patients we enrolled were diagnosed according to Chinese guidelines for treatment of adult primary immune thrombocytopenia: (1) Finding thrombocytopenia during a routine blood count at least twice. Blood film should be examined to exclude pseudothrombocytopenia and to check for morphological abnormalities of the blood cells. (2) Splenomegaly occurs infrequently in ITP patients. (3) Bone marrow examination is recommended. A bone marrow exam of ITP patients will show a normal or increased megakaryocyte count, with a decreased thrombocytenic megakaryocyte count. (4) Exclusion of secondary thrombocytopenia. The co-morbidity of patients were HT and DM, and there were no patients with other diseases such as stroke, heart, and hyperlipidemia. There were no patients used drugs such as antiplatelet, anticoagulant, ant-lipid. The patients enrolled didn't take any other medication other than glucocorticoid (Prednisone) for treatment of ITP such as thrombopoietin and rituximab. All participating patients provided written informed consent and completed questionnaires including personal information.

#### Cytokine analysis

Two milliliter of venous blood was collected from each volunteer, then 200 μl serum were separated by density gradient centrifugation for cytokines analysis. The levels of cytokines (IFN-γ, IL-1, IL-4, IL-6, IL-8, IL-10, IL-17A, IL-22, IL-23, TNF-α and TGF-β) were detected by using a cytoketric bead array (CBA) human inflammation kit according to the manufacturer's instructions (BD Pharmingen, San Diego, CA, USA) and analyzed by AimPlex Bead-based multiparametric flow cytometry (EPICS-Elite, Beckman-Coulter, USA). Briefly, AimPlex Bead-based Multiplexed Immunoassays for Flow are similar in principle to a sandwich ELISA, with each bead population conjugated with a specific capture antibody to trap the protein of interest, such as a cytokine, in a sample. The amount of the analyte captured is detected via a biotinylated antibody that recognizes a secondary epitope in the protein, followed by streptavidin-PE treatment. The fluorescence intensity of PE on the beads is quantified on a flow cytometer. The concentration of a protein of interest in a sample can be obtained by comparing the fluorescence signals of the sample to those of a standard curve generated from serial dilutions of a known concentration of the analyte.

#### Assessment of hemorrhage

The evaluation of bleeding was based on the patient history of bleeding and physical examination during the first week of consultation. The examination covered 9 anatomical sites including the skin, oral cavity, nose, gastrointestinal tract, urinary system, gynecological tract, lungs, intracranial and conjunctiva. Then, patients were divided into two groups according to ITP-BAT score, no bleeding group was 0 score, the others was bleeding group, which score was above 0.

#### Statistical analysis

R software was used for statistical analysis (Version 3.5.3; https://www.R-project.org). The least absolute shrinkage and selection operator (LASSO) method was used to select the optimal predictive features among risk factors for bleeding in patients with ITP because it is fit to constrain high-dimensionality data. Features without nonzero coefficients are excluded in the LASSO regression model. Then, a predictive model was built based on the results of multivariate logistic regression analysis, which also incorporated the results of the LASSO regression model. The odds ratio (OR), 95% confidence interval (CI) and P-value were calculated for all features. The statistical evaluations were all two-sided. Demographic characteristics with a P-value ≤ 0.05 were included in the model, and variables associated with disease or treatment characteristics were also included. All potential predictors were applied to develop a predictive model for the risk of bleeding by using the cohort.
Calibration curves were used to assess the calibration of the bleeding risk nomogram. A significant test statistic would indicate that the model was not perfectly calibrated. Then, the discrimination performance of the bleeding risk nomogram was quantified with the area under the receiver operating characteristic (ROC) curve and Harrell's C-index. Subsequently, bootstrapping validation (1,000 bootstrap resamples) was conducted to calculate a relatively corrected C-index for the bleeding risk nomogram. However, the clinical usefulness of the bleeding risk nomogram was detected by decision curve analysis, which quantified the net benefits at different threshold probabilities in the validation dataset. However, the method of calculating net benefit was to subtract the proportion of all false-positive patients from the proportion of true-positive patients and to weigh on consensus-based recommendation for target platelet counts for surgery or medical therapy in adults.

All patients data, including demographic and clinical characteristics, in the two groups are reported in Table 1. There were 100 patients of training cohort and 88 patients of validation cohort enrolled in this study, included persistent (3–12 months) and chronic (>12 months) patients with the platelet count range of 12–78 × 10⁹/L. All of the members were divided into bleeding and nonbleeding groups according to ITP-BAT score, no bleeding group was 0 score, the others was bleeding group, which score was above 0. The results for the expression of cytokines are shown for four groups, which were created by grouping by percentile (25%, 50%, and 75%). Additionally, patients were divided in three groups according to the platelet count based on consensus-based recommendation for target platelet counts for surgery or medical therapy in adults. All patients data, including demographic and clinical characteristics, in the two groups are reported in Table 1.

**Results**

**Patient characteristics.** There were 100 patients of training cohort and 88 patients of validation cohort enrolled in this study, included persistent (3–12 months) and chronic (>12 months) patients with the platelet count range of 12–78 × 10⁹/L. All of the members were divided into bleeding and nonbleeding groups according to ITP-BAT score, no bleeding group was 0 score, the others was bleeding group, which score was above 0. The results for the expression of cytokines are shown for four groups, which were created by grouping by percentile (25%, 50%, and 75%). Additionally, patients were divided in three groups according to the platelet count based on consensus-based recommendation for target platelet counts for surgery or medical therapy in adults. All patients data, including demographic and clinical characteristics, in the two groups are reported in Table 1.

**Feature selection.** The 19 features (shown in Table 1) of 100 patients were reduced to eight potential predictors based on the LASSO regression model. Dotted vertical lines were drawn at the optimal values by using the minimum criteria and the 1 standard error of the minimum criteria (the 1 SE criteria). A lambda value of 0.097, with log (lambda) = -3.37 was chosen (1 SE criteria) according to fivefold cross-validation (Fig. 1A,B). These features included the expression of IFN-γ, the expression of IL-4, the expression of IL-10, the expression of IL-17A, the expression of IL-22, the expression of TGF-β, the count of PLT and the length of time of ITP (Table 2). Then, logistic regression also performed for further verification. The results were showed in Table 2. Except PLT and IL-17A, the p value of the other 6 features are blew 0.05. However, PLT and IL-17A are meaning- ful to ITP, we still use the above 8 features for further forecasting.

**Prediction model.** According to the results of the LASSO regression analysis, 8 potential predictors were selected and analyzed by logistic regression for further forecasting. The results are shown in Table 2. Then, the forecast model that included the above independent predictors was developed and is presented as the nomogram (Fig. 2).

**Accuracy of the bleeding risk nomogram.** The nonadherence nomogram was subjected to internal verification and external verification. The calibration curve of the bleeding risk nomogram for the prediction of bleeding risk in ITP patients demonstrated good agreement in training cohort and validation cohort (Fig. 3). The C-index for the predictive nomogram was 0.82 (95% CI 0.73376–0.90624) for the training cohort and was confirmed to be 0.6689 through internal bootstrapping validation and 0.89 (95% CI 0.868, 0.902) in validation cohort, which suggested that the model had good discrimination. In addition, the AUC for the predictive nomogram was 0.79 in training cohort and 0.94 in validation cohort (Fig. 4), which also showed that the model had a good prediction ability. In the bleeding risk nomogram, apparent performance addressed the good prediction capability.

**Clinical application.** Decision curve analysis of the bleeding risk nomogram is presented in Fig. 5. The decision curve showed that if the threshold probability of a patient was >14 and <88%, using this bleeding risk nomogram to predict bleeding risk added more benefit than the scheme did. Within this range, using the bleeding risk nomogram developed in the current study to predict bleeding risk added more benefit than the intervention-all-patients scheme or the intervention-none scheme.

**Discussion**

Currently, risk nomograms are widely used as prognostic models for clinical decision-making. For ITP patients, bleeding risk still remains an enormous burden that affects quality of life. Although compared with patients with other hemorrhagic diseases, the majority of ITP patients have relatively mild bleeding symptoms, an objective and accurate description is still needed to study the heterogeneity of bleeding tendency in this disease. However, a useful model is still lacking for assessing bleeding risk. Therefore, it is necessary to construct a risk nomogram that can be used by clinicians to clarify and control the risk of bleeding.

However, ITP is considered to be a consequence of complex immunoregulation disorder events in T cells, B cells and related cytokines. Previous studies showed that the development of ITP was connected with immunoregulation disorder caused by Th1/Th2 and Th17/Treg cell biases and abnormal secretion by Bregs. Th cells play a central role in the maintenance of the immune balance. The Th1/Th2 and Th17/Treg cytokine axes are closely associated with autoimmunity. Upon antigen stimulation, CD4+ T cells can differentiate into at least four functional subtypes (Th1, Th2, Th17 and Treg), which have unique patterns of effector cytokine secretion. Th1, Th2, Th17 and Treg cells are differentiated from Th0 cells. Th1 cells secrete the specific cytokine IFN-γ, Th2 cells secrete the specific cytokine interleukin-4 (IL-4), T helper 17 (Th17) cells secrete the specific cytokine...
| Demographic characteristics | Training cohort (%) | Validation cohort (%) | P     |
|-----------------------------|---------------------|-----------------------|-------|
| Age                         |                     |                       |       |
| 18–60                       | 51 (78.5)           | 29 (82.9)             | 0.6   |
| ≥60                         | 14 (21.5)           | 6 (17.1)              |       |
| Gender                      |                     |                       |       |
| Male                        | 23 (35.4)           | 10 (28.6)             | 0.48  |
| Female                      | 42 (64.6)           | 25 (71.4)             |       |
| Education level             |                     |                       |       |
| Primary school              | 21 (32.3)           | 10 (28.6)             | 0.78  |
| Middle school               | 26 (40)             | 13 (37.1)             |       |
| University                  | 18 (27.7)           | 12 (34.3)             |       |
| Occupational                |                     |                       |       |
| Non-manual labor            | 40 (61.5)           | 23 (65.7)             | 0.68  |
| Physical labor              | 25 (38.5)           | 12 (34.3)             |       |
| Clinical characteristics    |                     |                       |       |
| Disease duration (months)   |                     |                       |       |
| 3–12                        | 11 (16.9)           | 5 (14.3)              | 0.73  |
| >12                         | 54 (83.1)           | 30 (85.7)             |       |
| Comorbidities               |                     |                       |       |
| Hypertension                | 6 (9.2)             | 3 (8.5)               | 0.9   |
| Diabetes                    | 1 (1.5)             | 1 (2.8)               | 2 (4.7)|
| No comorbidities            | 58 (90.3)           | 31 (89.3)             |       |
| Current use of GC           |                     |                       |       |
| Yes                         | 40 (61.6)           | 21 (60)               | 0.87  |
| No                          | 25 (38.4)           | 14 (40)               |       |
| PLT (× 10^9/L)              |                     |                       |       |
| < 20                        | 22 (33.9)           | 3 (8.6)               | 0.02  |
| 20–50                       | 29 (44.6)           | 20 (57.1)             |       |
| 51–80                       | 14 (21.5)           | 12 (34.3)             |       |
| IFN-γ (pg/ml)               |                     |                       |       |
| < 4.25                      | 13 (20)             | 10 (28.6)             | 0.72  |
| 4.25–5.02                   | 18 (27.7)           | 9 (25.7)              |       |
| 5.03–16.4                   | 18 (27.7)           | 7 (20)                |       |
| > 16.4                      | 16 (24.6)           | 9 (25.7)              |       |
| IL-1β (pg/ml)               |                     |                       |       |
| < 1.57                      | 15 (25.1)           | 10 (28.6)             | 0.48  |
| 1.57–2.84                   | 18 (27.7)           | 6 (17.1)              |       |
| 2.85–125.31                 | 18 (27.7)           | 8 (22.9)              |       |
| > 125.31                    | 14 (21.5)           | 11 (31.4)             |       |
| IL-4 (pg/ml)                |                     |                       |       |
| < 3.17                      | 19 (29.2)           | 5 (14.3)              | 0.36  |
| 3.17–3.71                   | 15 (25.1)           | 11 (31.4)             |       |
| 3.72–12.59                  | 14 (21.5)           | 10 (28.6)             |       |
| > 12.59                     | 17 (26.2)           | 9 (25.7)              |       |
| IL-6 (pg/ml)                |                     |                       |       |
| < 6.02                      | 15 (25.1)           | 10 (28.6)             | 0.26  |
| 6.02–8.46                   | 19 (29.2)           | 6 (17.1)              |       |
| 8.47–9.855.8                | 18 (27.7)           | 7 (20)                |       |
| > 9.855.8                   | 13 (20)             | 12 (34.3)             |       |
| IL-8 (pg/ml)                |                     |                       |       |
| < 19.17                     | 20 (30.8)           | 5 (14.3)              | 0.31  |
| 19.17–41.49                 | 14 (21.5)           | 10 (28.6)             |       |
| 41.5–441.872                | 16 (24.6)           | 9 (25.7)              |       |
| > 441.872                   | 15 (25.1)           | 11 (31.4)             |       |

Continued
IL-17A, and Treg cells secrete the specific cytokine TGF-β. Breg cells are another kind of immunoregulatory cell that secretes the specific cytokines IL-10 and IL-22. Generally, cytokines can be divided into two types depending on their function. One type is proinflammatory, and the other is anti-inflammatory. The expression of proinflammatory and anti-inflammatory factors tends to be balanced under physiological conditions; otherwise, immune disorders occur.

Additionally, cytokines are derived from immune cells, and the secretion and function of immune cells are regulated by related cytokines. In other words, the occurrence and development of ITP is due to the overexpression of proinflammatory factors and low expression of anti-inflammatory factors, according to research. Since cytokines are so important in the onset of ITP, cytokines should be incorporated into bleeding models. However, previous hemorrhagic risk assessment models did not take cytokines into account. In this study, a relatively accurate predictive tool was used to evaluate bleeding risk in patients with ITP. The internal validation and external validation of the tool showed good discrimination and calibration capabilities; in particular, our high c-index measured by interval validation and AUC indicate that our model can be used widely and accurately to assess bleeding risk.

Regarding the risk of bleeding in ITP patients, a previous studies mainly focused on the effect of platelets, including the platelet count, platelet function, platelet activation, and the immature platelet fraction. However, these models, such as the ITP-BAT, WHO bleeding scoring system, Buchanan hemorrhage score, and Khellaf hemorrhage score, are based on only clinical hemorrhagic symptoms. It is difficult to assess the risk of bleeding in a patient if he or she bled previously, but the symptoms have disappeared or no positive signs of bleeding are found on physical examination. At this time, the risk of bleeding is underestimated, which affects treatment choice. Additionally, low platelet counts do not always indicate a high bleeding risk; therefore, if treatment is based only on platelet counts, overtreatment may occur, resulting in wasted medical resources and forcing patients to take unnecessary medical risks. In addition, platelet function detection methods include optical turbidimetry, the impedance method, thromboelastography, Plateletwork tests and flow cytometry. However, these methods have some defects, such as poor replicability, a requirement for a high platelet quantity.

### Table 1. Characteristics of patients in the training and validation cohorts. GC glucocorticoid (Prednisone).

| Cytokine | Training cohort (%) | Validation cohort (%) |
|----------|---------------------|-----------------------|
|         | Bleeding n (%)      | No Bleeding n (%)     |       | Bleeding n (%) | No Bleeding n (%) |       |
| IL-10 (pg/ml) | | | | | | |
| < 3.99  | 14 (21.5)          | 11 (31.4)          | 0.73  | 4 (9.3)        | 4 (8.9)        | 0.46  |
| 3.99–4.75 | 16 (24.6)          | 8 (22.9)           | 4.76–12.98 | 19 (29.2) | 8 (22.9) | 21 (48.8) | 28 (62.2) | 0.29  |
| > 12.98 | 16 (24.7)          | 8 (22.9)           |       | 1 (2.3)        | 2 (4.4)        |       |
| IL-17A (pg/ml) | | | | | | |
| < 143.65 | 20 (30.8)          | 5 (14.3)           |       | 6 (14)         | 7 (15.6)       | 0.06  |
| 143.65–179.38 | 17 (26.2) | 8 (22.9) | 6 (14) | 7 (15.6) | 0.06  |
| > 179.39–480.2 | 17 (26.2) | 8 (22.9) | 29 (67.4) | 25 (55.6) | 0.06  |
| > 480.2 | 11 (16.8)          | 14 (40)            |       | 3 (7)          | 2 (4.4)        |       |
| IL-22 (pg/ml) | | | | | | |
| < 5.26  | 20 (30.8)          | 5 (14.3)           |       | 8 (18.6)       | 11 (24.4)      | 0.12  |
| 5.26–6.8 | 18 (27.7)          | 7 (20)             |       | 17 (39.5)      | 14 (31.1)      | 0.06  |
| > 6.81–2,743.68 | 14 (21.5) | 11 (31.4) | 16 (37.2) | 18 (40) | 0.06  |
| > 2,743.68 | 13 (20)            | 12 (34.3)          |       | 2 (4.7)        | 2 (4.4)        |       |
| IL-23 (pg/ml) | | | | | | |
| < 2.43  | 16 (24.6)          | 9 (25.7)           | 0.3   | 11 (25.6)      | 15 (33.3)      | 0.83  |
| 2.43–3.24 | 20 (30.8)          | 5 (14.3)           |       | 12 (27.9)      | 11 (24.4)      | 0.83  |
| 3.25–340.81 | 14 (21.5) | 11 (31.4) | 8 (18.6) | 9 (20) | 0.12  |
| > 340.81 | 15 (25.1)          | 10 (28.6)          |       | 12 (27.9)      | 10 (22.2)      |       |
| TNF-α (pg/ml) | | | | | | |
| < 2.24  | 19 (29.2)          | 5 (14.3)           |       | 13 (30.2)      | 12 (26.7)      | 0.29  |
| 2.24–2.99 | 15 (25.1)          | 11 (31.4)          |       | 16 (37.2)      | 14 (31.1)      | 0.49  |
| > 2,115.84 | 17 (26.2) | 8 (22.9) | 11 (25.6) | 11 (24.4) | 0.49  |
| > 15.84 | 14 (21.5)          | 11 (31.4)          |       | 3 (7)          | 8(17.8)        |       |
| TGF-β (pg/ml) | | | | | | |
| < 6,959.06 | 20 (30.8) | 6 (17.1) | 14 (32.6) | 11 (24.4) | 0.05  |
| 6,959.06–12,480.82 | 18 (27.7) | 7 (20) | 19 (44.2) | 5 (11.1) | 0.01  |
| 12,480.83–67,139.67 | 17 (26.2) | 8 (22.9) | 8 (18.6) | 15 (33.3) | 0.01  |
| > 67,139.67 | 10 (15.3) | 14 (40) | 2 (4.7) | 14 (31.1) | 0.01  |
In this study, 65% of ITP patients exhibited bleeding, including in the purpura, muscle, nose, retinal and gingival. Then, we obtained eight key factors that forecasted the risk of bleeding in ITP patients by risk factor analysis. This nomogram suggested that patients with high expression of IFN-γ, IL-17A, and IL-22; low expression of IL-4, IL-10, and TGF-β; a low platelet count, and a long course of disease had an elevated risk of bleeding. This result basically agreed with clinical feature findings. Therefore, it is helpful to take into account cytokines when predicting bleeding risk. This model will assist physicians in accessing the bleeding risk of ITP patients and taking interventions in time, preventing unnecessary measures in low-risk situations and avoiding delays or discontinuity in treatment when the most appropriate time appears. We also believe that this model
Figure 2. The nomogram of bleeding risk predict model. Note To use the nomogram, an individual patient's value is located on each variable axis, and a line is drawn upward to estimate the number of points received for each variable value. The sum of these numbers is located on the Total Points axis, and a line is drawn downward to the survival axes to determine the likelihood of bleeding.

Figure 3. Calibration curves for bleeding nomogram predictions in the training cohort (A) and Validation cohort (B). Notes The x-axis represents the forecasted bleeding risk, while the the actual diagnosed bleeding shown at y-axis. The diagonal dotted line showed an ideal model for the perfect prediction ability, and the solid line (bias-corrected line) represents the reality performance of the nomogram. The closer fit to the diagonal dotted line, the better prediction ability of the nomogram.
Figure 4. ROC curves of bleeding nomogram in the training cohort (A) and validation cohort (B). Notes: The y-axis represents true positive rate and x-axis shows false positive rate. The area between dotted line and the curve is AUC, and the larger of AUC (closed to one), is the higher of model's accuracy. Then, the accuracy of bleeding risk model shows great based on AUC.

Figure 5. Decision curve analysis for the bleeding risk nomogram. The y-axis measures the net benefit. The blue line represents the bleeding risk nomogram. The thin solid line represents the assumption that all patients were bleeding during the course of ITP progression. The thick solid line (parallel to the x-axis) represents the assumption that no patients were bleeding. The net benefit was calculated by subtracting the proportion of all patients who are false positive from the proportion who are true positive, weighting by the relative harm of forgoing treatment compared with the negative consequences of an unnecessary treatment. In this study, 14% (the intersection of blue line and thin solid line) was false positive rate and 88% (the intersection of blue line and thick solid line) was false negative rate.
will be beneficial in the evaluation of drug efficacy since improvements in patients with bleeding symptoms are as important as improvements in platelet levels.

Limitations
There are also several limitations of our current study. First, our study did not enroll newly diagnosed patients (less than 3 months) and the platelet level as 80–< 100 were not included, so the bleeding risk for these patients cannot be evaluated. Second, children and teenagers were not included, so the difference between pediatric and adult patients was not be taken into consideration. Third, the cohort was not representative of all Chinese patients with ITP since patient race and region of origin were not considered. These factors need to be externally evaluated in a broader population of ITP patients.

Received: 30 September 2019; Accepted: 26 August 2020

Published online: 18 September 2020

References
1. Rodeghiero, F. & Ruggeri, M. ITP and international guidelines: what do we know, what do we need?. Presse Med. 43, e61–e67. https://doi.org/10.1016/j.pmed.2014.01.005 (2014).
2. Zufferey, A., Kapur, R. & Semple, J. W. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J. Clin. Med. https://doi.org/10.3390/jcm6020016 (2017).
3. Takahashi, N. et al. The cytokine polymorphisms affecting Th1/Th2 increase the susceptibility to, and severity of, chronic ITP. BMC Immunol. 18, 26–37. https://doi.org/10.1186/s12865-017-0210-3 (2017).
4. Guo, N. H. et al. The potential therapeutic benefit of resveratrol on Th17/Treg imbalance in immune thrombocytopenic purpura. Int. Immunopharmacol. 73, 181–192. https://doi.org/10.1016/j.intimp.2019.04.061 (2019).
5. Zhao, X. et al. Idiopathic thrombocytopenic purpura: pathogenesis and potential therapeutic approach. Minerva Med. 108, 502–506. https://doi.org/10.23736/S0026-4532.17.05252-1 (2017).
6. Talaat, R. M., Elmaghraby, A. M., Barakat, S. S. & El-Shahat, M. L. Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP). Clin. Exp. Immunol. 176, 291–300. https://doi.org/10.1111/cei.12279 (2014).
7. Iwata, S. et al. The transcription factor T-bet limits amplification of type I IFN transcriptome and circuitry in T helper 1 cells. Immunity 46, 983–991. https://doi.org/10.1016/j.immuni.2017.05.005 (2017).
8. Pelhivan, M. et al. Investigation of TNF-alpha, TGF-beta 1, IL-10, IL-6, IFN-gamma, MBL, GPIA, and IL1A gene polymorphisms in patients with idiopathic thrombocytopenic purpura. Platelets 22, 588–595. https://doi.org/10.3109/09537104.2011.577255 (2011).
9. Provan, D. et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115, 168–166 (2010).
10. Medeiros, N. I. & Gomes, J. A. Cytometric bead array (CBA) for measuring cytokine levels in chagas disease patients. Methods Mol. Biol. 309–314, 2019. https://doi.org/10.1007/978-1-4939-9148-8_23 (2019).
11. Morgan, E. et al. Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin. Immunol. 110, 252–266. https://doi.org/10.1016/j.clim.2003.11.017 (2004).
12. Page, L. K. et al. The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. Br J Haematol. 138(2), 245–248 (2007).
13. Liu, B. et al. Prediction of prostate cancer aggressiveness with a combination of radiomics and machine learning-based analysis of dynamic contrast-enhanced MRI. Clin. Radiol. 74(896), e896.e8. https://doi.org/10.1016/j.crad.2019.07.011 (2019).
14. Wang, H. et al. Predicting medication nonadherence risk in a Chinese inflammatory rheumatic disease population: development and assessment of a new predictive nomogram. Patient Prefer Adherence. 12, 1775–1785. https://doi.org/10.2147/PAPA.S159293 (2018).
15. Iasonos, A., Schrag, D., Raj, G. V. & Panageas, K. S. How to build and interpret a nomogram for cancer prognosis. J. Clin. Oncol. 25, 252–266. https://doi.org/10.1001/jco.2007.12.9791 (2008).
16. Tscheiki-Gratil, F. et al. Lost in calibration: why people still do not calibrate their models, and why they still should: a case study from urban drainage modelling. Water Sci. Technol. 74, 2337–2348. https://doi.org/10.2166/wst.2016.395 (2016).
17. Pencina, M. J. & D’Agostino, R. B. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat. Med. 23, 2109–2123. https://doi.org/10.1002/sim.1802 (2004).
18. Akobeng, A. K. Understanding diagnostic tests 3: Receiver operating characteristic curves. Acta Paediatr. 96, 644–647. https://doi.org/10.1111/j.1651-2227.2006.00178.x (2007).
19. Van-Calbster, B. et al. Reporting and interpreting decision curve analysis: a guide for investigators. Eur. Urol. 74, 796–804. https://doi.org/10.1016/j.eururo.2018.08.038 (2018).
20. Huang, Y. Q. et al. Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer. J. Clin. Oncol. 34, 2157–2164. https://doi.org/10.1200/JCO.2015.65.9128 (2016).
21. Provan, D. et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 3(22), 3780–3817 (2019).
22. Hsu, F. et al. Aberrant frequency of IL-10-producing B cells and its association with Treg/Th17 in adult primary immune thrombocytopenia patients. Biomol. Res. Int. 2014, 571302. https://doi.org/10.1155/2014/571302 (2014).
23. Yu, S. et al. Inactivation of Notch signaling reverses the Th17/Treg imbalance in cells from patients with immune thrombocytopenia. Lab. Invest. 95, 157–167. https://doi.org/10.1038/labinvest.2014.142 (2015).
24. Liu, H. et al. Involvement of levels of Toll like receptor-4 in monocytes, CD4+ T-lymphocyte subsets, and cytokines in patients with immune thrombocytopenia purpura. J. Thromb. Res. 132, 196–201. https://doi.org/10.1016/j.jthromres.2016.06.042 (2013).
25. Aslam, R. et al. Thymic retention of CD4+CD25+FoxP3+ T regulatory cells is associated with their peripheral deficiency and thrombocytopenia in a murine model of immune thrombocytopenia. Blood 120, 2127–2132. https://doi.org/10.1182/blood-2012-02-413526 (2012).
26. Perricone, C. et al. Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases. Immunol. Res. 60, 226–235. https://doi.org/10.1007/s12026-014-8397-4 (2014).
27. Gomez-Almaguer, D. Monoclonal antibodies in the treatment of immune thrombocytopenic purpura (ITP). Hematology 17(Suppl 1), S25–S27. https://doi.org/10.1023/S:102533121X133861951523 (2012).
28. Wang, M. J. et al. Secretory imbalance between pro-inflammatory and anti-inflammatory cytokines in the patients with immune thrombocytopenia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 26, 522–527. https://doi.org/10.7534/j.issn.1009-2157.2018.02.036 (2018).
29. Qu, M. et al. Low platelet count as risk factor for infections in patients with primary immune thrombocytopenia: a retrospective evaluation. Ann. Hematol. 97, 1701–1706. https://doi.org/10.1007/s00277-018-3367-9 (2018).
30. Frelinger, A. R. et al. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. *Blood* **126**, 873–879. https://doi.org/10.1182/blood-2015-02-628461 (2015).
31. Li, J., Sullivan, J. A. & Ni, H. Pathophysiology of immune thrombocytopenia. *Curr. Opin. Hematol.* **38**, 33–38. https://doi.org/10.1097/MOH.0000000000000542 (2018).
32. Michelson, A. D. Immature platelet fraction in immune thrombocytopenia: useful in diagnosis but does it predict bleeding?. *Pediatr. Blood Cancer* https://doi.org/10.1002/pbc.26842 (2018).
33. Rodeghiero, F. et al. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. *Blood* **121**, 2596–2606. https://doi.org/10.1182/blood-2012-07-442392 (2013).
34. Fogarty, P. F. et al. Selective validation of the WHO bleeding scale in patients with chronic immune thrombocytopenia. *Curr. Med. Res. Opin.* **28**, 79–87. https://doi.org/10.1111/j.1365-2281.2011.04226.x (2012).
35. Buchanan, G. R. & Adix, L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. *J. Pediatr.* **141**, 683–688. https://doi.org/10.1016/j.jpeds.2012.12.057 (2002).
36. Khellaf, M., Michel, M., Schaeffer, A., Rierling, P. & Godeau, B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. *Haematologica* **90**, 829–832 (2005).
37. Hvas, A. M. & Favaloro, E. J. Platelet function analyzed by light transmission aggregometry. *Methods Mol Biol.* **1646**, 321–331. https://doi.org/10.1007/978-1-4939-7196-1_25 (2017).
38. Freer, C. et al. Assessment of platelet function on the routine coagulation analyzer Sysmex CS-2000i. *Platelets* **29**, 95–97. https://doi.org/10.1080/09537104.2017.1353683 (2018).

Acknowledgements
This work was supported by the National Program on Key Basic Research Project (2015CB554403).

Author contributions
Conception and design: M.W., X.H. Administrative support: X.D., X.H., Y.X. Collection and assembly of data: W.L., H.W., X.G., R.Q., H.C., S.Z., T.F., Y.S., Y.L. Graph drawing: M.W., X.Z.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to X.H.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020